FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249210216> ?p ?o ?g. }

• W4249210216 endingPage "3100" @default.
• W4249210216 startingPage "3093" @default.
• W4249210216 abstract "Journal of Ultrasound in MedicineVolume 38, Issue 12 p. 3093-3100 Practice ParameterFree Access AIUM Practice Parameter for the Performance of Detailed Second- and Third-Trimester Diagnostic Obstetric Ultrasound Examinations First published: 17 November 2019 https://doi.org/10.1002/jum.15163Citations: 16AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Introduction The clinical aspects of this practice parameter were developed collaboratively among the American Institute of Ultrasound in Medicine (AIUM) and other organizations whose members use ultrasound for performing detailed second- and third-trimester diagnostic obstetric ultrasound examinations (see “Acknowledgments”). Recommendations for personnel requirements, the written request for the examination, documentation, quality control, and safety may vary among the organizations and may be addressed by each separately. The detailed obstetric ultrasound examination (Current Procedural Terminology [CPT] code 76811) is not intended to be the routine ultrasound examination performed for all pregnancies. Rather, it is an indication-driven examination performed for a known or suspected fetal anatomic abnormality, known fetal growth disorder, genetic abnormality, or increased risk for a fetal anatomic or genetic abnormality or placenta accreta spectrum (PAS). Performance and interpretation of a detailed fetal anatomic scan require advanced skills and knowledge and the ability to effectively communicate the findings to the patient and her referring physician. Thus, the performance of the detailed obstetric examination should be rare outside referral practices with special expertise in the identification and diagnosis of fetal anomalies and placental implantation disorders. Only 1 such medically indicated study per pregnancy per practice is appropriate. If 1 or more required structures are not adequately demonstrated during the 76811 examination, the patient may be brought back for a focused assessment (CPT code 76816). A second detailed obstetric examination should not be performed unless there are extenuating circumstances. Indications Indications for a detailed fetal anatomic examination include, but are not limited to, the following conditions: Previous fetus or child with a congenital, genetic, or chromosomal abnormality1, 2; Known or suspected fetal anomaly or known or suspected fetal growth restriction in the current pregnancy2, 3; Fetus at increased risk for a congenital anomaly, such as the following: Maternal pregestational diabetes or gestational diabetes diagnosed before 24 weeks’ gestation4-8; Pregnancy conceived via assisted reproductive technology9; Maternal body mass index of 30 kg/m2 or higher10-13; Multiple gestations10, 14; Abnormal maternal serum analytes15; Teratogen exposure16; First-trimester nuchal translucency measurement of 3.0 mm or greater17; Fetus at increased risk for a genetic or chromosomal abnormality, such as the following: Parental carrier of a chromosomal or genetic abnormality1, 2; Maternal age of 35 years or older at delivery1, 2; Positive screening test results for aneuploidy1, 2; Aneuploidy marker noted on an ultrasound examination1, 10; First-trimester nuchal translucency measurement of 3.0 mm or greater17-19; Other conditions affecting the fetus, including the following: Congenital infections3, 16, 20, 21; Maternal drug use16; Alloimmunization22, 23; Oligohydramnios10; Polyhydramnios10, 24; and Suspected placenta PAS or risk factors for PAS such as placenta previa in the third trimester or a placenta overlying a prior cesarean scar site.10, 25, 26 Qualifications and Responsibilities of Personnel See www.aium.org for AIUM Official Statements, including Standards and Guidelines for the Accreditation of Ultrasound Practices and relevant Training Guidelines. If the physician does not personally perform the examination, he or she must provide general supervision, as defined by the Centers for Medicare and Medicaid Services Code of Federal Regulations 410.32: “General supervision means the procedure is furnished under the physician's overall direction and control, but the physician's presence is not required during the performance of the procedure. Under general supervision, the training of nonphysician personnel who actually perform the diagnostic procedure and the maintenance of the necessary equipment and supplies are the continuing responsibility of the physician.” If a sonographer performs the ultrasound examination, that individual should be credentialed in accordance with the AIUM accreditation policies. Written Request for the Examination The written or electronic request for an ultrasound examination should provide sufficient information to allow for the appropriate performance and interpretation of the examination. The request for the examination must originate from a physician or other appropriately licensed health care provider or under the provider's direction. The accompanying clinical information should be provided by a physician or appropriate health care provider familiar with the patient's clinical situation and should be consistent with relevant legal and local health care facility requirements. Specifications of the Examination A detailed comprehensive obstetric ultrasound examination (76811) includes all of the components of a standard fetal ultrasound examination (CPT code 76805). The additional specific examination content beyond that included in the standard examination is determined by both the indication for the examination and the ultrasound findings identified during the examination and is guided by the specialized knowledge and training of the responsible physician. The specific elements of a given detailed obstetric ultrasound examination may be individualized based on these considerations. Therefore, a prescriptive approach to providing universally required detailed examination content is neither taken nor congruent with the nature of this indication-driven examination. The table provides a list of elements that may be included in a detailed examination. Based on the previously noted considerations, not all of these elements may be indicated in all detailed obstetric ultrasound examinations. Likewise, obtaining additional elements not listed in the table may be warranted. Table Table. Components of CPT Code 76811 (Standard and Detailed Examinations) Component Standard Detailed* Head and neck Lateral cerebral ventricles Choroid plexus Midline falx Cavum septi pellucidi Cerebellum Cisterna magna 3rd ventricle27 4th ventricle27 Lateral ventricular wall integrity, contour, ependymal lining27 Cerebellar lobes, vermis, and cisterna magna28 Corpus callosum29 Integrity and shape of cranial vault30 Brain parenchyma31 Neck32, 33 Face Upper lip Profile34-36 Nasal bone (15–22 wk)37-40 Coronal face (nose/lips/lens)34 Palate, maxilla, mandible, and tongue41, 42 Ear position and size Orbits Chest Heart Cardiac activity 4-chamber view Left ventricular outflow tract Right ventricular outflow tract 3-vessel view (if technically feasible)44 3-vessel and trachea view (if technically feasible)44 Situs Aortic arch Superior and inferior venae cavae43 Ductal arch Interventricular septum 3-vessel view44 3-vessel and trachea view44 Thorax Lungs45, 46 Integrity of diaphragm47 Ribs48, 49 Abdomen Stomach (presence, size, and situs) Kidneys Urinary bladder Cord insertion site into fetal abdomen Umbilical cord vessel number Small and large bowel50-52 Adrenal glands53 Gallbladder54, 55 Liver56 Renal arteries57 Spleen Integrity of abdominal wall58 Spine Cervical Thoracic Lumbar Sacral spine Integrity of spine and overlying soft tissue59, 60 Shape, curvature, conus medullaris61, 62 Extremities Legs Arms Hands Feet Number, architecture, and position61-65 Digits of hands and feet: number and position65-68 Genitalia In multiple gestations When medically indicated External genitalia69 Placenta Location Relationship to internal os Appearance Placental cord insertion Masses70, 71 Accessory/succenturiate lobe with location of connecting vascular supply to primary placenta and internal cervical os72, 73 Implantation site with evaluation for abnormal adherence25 Standard evaluation Fetal number Presentation Qualitative or semiquantitative estimate of amniotic fluid Maternal anatomy Cervix (transvaginal when indicated) Uterus Adnexa Biometry Biparietal diameter Head circumference Femur length Abdominal circumference Fetal weight estimate Cerebellum74 Inner and outer orbital diameters75 Nuchal fold thickness (16–20 wk)37-39 Humerus37-39 Ulna/radius Tibia/fibula * As noted in the text of this Practice Parameter, all of these elements may not be indicated in every detailed obstetric ultrasound examination. Likewise, obtaining additional elements not listed in the table may be warranted. Documentation Adequate documentation is essential for high-quality patient care. Ultrasound images that contain diagnostic information and/or direct patient treatment (both normal and abnormal) should be recorded in accordance with the AIUM Practice Parameter for Documentation of an Ultrasound Examination. Equipment Specifications These studies should be conducted with real-time scanners, using a transabdominal and/or transvaginal approach. Real-time ultrasound is necessary to confirm the presence of fetal life through observation of cardiac activity and active fetal movement. The choice of transducer frequency is a trade-off between beam penetration and resolution. A transducer of an appropriate frequency should be used. With modern equipment, 3-MHz and higher abdominal transducers allow sufficient penetration in most patients while providing adequate resolution. Color and/or pulsed Doppler ultrasound may be used as warranted, based on the indication for and findings identified during the detailed examination. If additional billing charges would be incurred by using these additional modalities, specific orders from the referring clinician for their use may be needed. ALARA Principle The potential benefits and risks of each examination should be considered. The ALARA (as low as reasonably achievable) principle should be observed when adjusting controls that affect the acoustic output and by considering transducer dwell times. Further details on ALARA may be found in the AIUM publication Medical Ultrasound Safety, Third Edition.76 Fetal Safety Diagnostic ultrasound studies of the fetus are generally considered safe during pregnancy (Conclusions Regarding Epidemiology for Obstetric Ultrasound). This procedure should be performed only when there is a valid medical indication (Prudent Use in Pregnancy ), and the lowest possible ultrasonic exposure setting should be used to gain the necessary diagnostic information under the ALARA principle. The output display standard, an on-screen real-time display of acoustic output, should be visible and monitored for the thermal index (TI) and mechanical index. The dwell time should be kept to a minimum. A TI for soft tissue (TIs) should be used at or before 10 weeks’ gestation, and a TI for bone (TIb) should be used at or after 10 weeks’ gestation when bone ossification is evident (Recommended Maximum Scanning Times for Displayed Thermal Index (TI) Values). In keeping with the ALARA principle, M-mode imaging should be used instead of spectral Doppler imaging to document the embryonic/fetal heart rate (Statement on Measurement of Fetal Heart Rate). Doppler ultrasound may be used to answer specific clinical questions. Spectral pulsed Doppler ultrasound is associated with higher energy output and should be used judiciously as part of an evaluation for anomalies. The promotion, selling, or leasing of ultrasound equipment for making “keepsake fetal videos” is considered by the US Food and Drug Administration to be an unapproved use of a medical device. Use of a diagnostic ultrasound system for keepsake fetal imaging, without a physician's order, may be in violation of state laws or regulations. Quality Control and Improvement, Safety, Infection Control, and Patient Education Policies and procedures related to quality control, patient education, infection control, and safety, including equipment performance monitoring, should be developed and implemented in accordance with the AIUM's Standards and Guidelines for the Accreditation of Ultrasound Practices. Acknowledgments This parameter was developed by the AIUM in collaboration with the American College of Radiology (ACR), the American College of Obstetricians and Gynecologists (ACOG), the American College of Osteopathic Obstetricians and Gynecologists (ACOOG), the Perinatal Quality Foundation (PQF), the Society of Diagnostic Medical Sonography (SDMS), the Society for Maternal-Fetal Medicine (SMFM), and the Society of Radiologists in Ultrasound (SRU) according to the process described in the AIUM Clinical Standards Committee Manual. Collaborative Subcommittees Members represent their societies in the initial version and final revision of this parameter. AIUM: Joseph R. Wax, MD, chair Anthony C. Sciscione, DO Isabelle A. Wilkins, MD ACR: Beverly G. Coleman, MD Carol B. Benson, MD ACOG: Joan M. Mastrobattista, MD ACOOG: Eric Carlson, DO, MPH PQF: Jean Spitz, MPH, CAE, RDMS SDMS: Joie Burns, MS, RT(R)(S), RDMS, RVT SMFM: Camille M. Kanaan, MD SRU: Ruth B. Goldstein, MD Deborah Levine, MD AIUM Clinical Standards Committee Bryann Bromley, MD, chair James M. Shwayder, MD, JD, vice chair Nirvikar Dahiya, MD Rob Goodman, MBBCh, MBA, BMSc Rachel Bo-ming Liu, MD Jean Spitz, MPH, CAE, RDMS John Stephen Pellerito, MD AIUM Expert Reviewers Bryann Bromley, MD Timothy Canavan, MD, MSc Julia Solomon, MD, CM References 1 American College of Obstetricians and Gynecologists. Practice Bulletin No. 163: screening for fetal aneuploidy. Obstet Gynecol 2016; 127: e123– e137. 2 American College of Obstetricians and Gynecologists. Practice Bulletin No. 162: diagnostic testing for genetic disorders. Obstet Gynecol 2016; 127: e108– e122. 3 American College of Obstetricians and Gynecologists. Practice Bulletin No. 204: fetal growth restriction. Obstet Gynecol 2019; 133: e97– e109. 4 American College of Obstetricians and Gynecologists. Practice Bulletin No. 201: pregestational diabetes mellitus. Obstet Gynecol 2018; 132: e228– e248. 5 American College of Obstetricians and Gynecologists. Practice Bulletin No. 190: gestational diabetes mellitus. Obstet Gynecol 2018; 131: e49– e64. 6 Society of Obstetricians and Gynaecologists of Canada. Clinical Practice Guideline No. 200: teratogenicity associated with pre-existing and gestational diabetes. J Obstet Gynaecol Can 2007; 29: 927– 934. 7Bartha JL, Martinez-Del Fresno P, Comino-Delgado R. Early diagnosis of gestational diabetes mellitus and prevention of diabetes-related complications. Eur J Obstet Gynecol 2003; 109: 41– 44. 8Aberg A, Westbrook L, Kallen B. Congenital malformations among infants whose mothers had gestational diabetes. Early Hum Dev 2001; 61: 85– 95. 9Davies MJ, Moore VM, Willson KJ, et al. Reproductive technologies and the risk of birth defects. N Engl J Med 2012; 366: 1803– 1813. 10Reddy UM, Abuhamad AZ, Levine D, Saade GR. Fetal imaging: executive summary of a joint Eunice Kennedy Shriver National Institute of Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound fetal imaging workshop. Am J Obstet Gynecol 2014; 210: 387– 397. 11Wax JR, Benacerraf BR, Copel J, et al. Consensus report on the 76811 scan: modification. J Ultrasound Med 2015; 34: 1915. 12Rasmussen SA, Chu SY, Kim SY, Schmid CH, Lau J. Maternal obesity and risk of neural tube defects: a meta-analysis. Am J Obstet Gynecol 2008; 198: 611– 619. 13Stothard KJ, Tennant PW, Bell R, Rankin J. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA 2009; 301: 636– 650. 14Chauhan SP, Scardo JA, Hayes E, Abuhamad AZ, Berghella V. Twins: prevalence, problems, and preterm births. Am J Obstet Gynecol 2010; 203: 305– 315. 15McPherson E, Thomas D, Manlick C, et al. Extreme values of maternal serum analytes in second trimester screening: looking beyond trisomy and NTDs. J Genet Couns 2011; 20: 396– 403. 16Rasmussen SA, Erickson JD, Reef SE, Ross DS. Teratology: from science to birth defects prevention. Birth Defects Res A Clin Mol Teratol 2009; 85: 82– 92. 17Reynders CS, Pauker SP, Benacerraf BR. First trimester isolated fetal nuchal lucency: significance and outcome. J Ultrasound Med 1997; 16: 101– 105. 18Nicolaides KH, Azar G Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defect in first trimester of pregnancy. BMJ 1992; 304: 867– 869. 19Comstock CH, Malone FD, Ball RH, et al. Is there a nuchal translucency millimeter measurement above which there is no additional benefit from first trimester serum screening? Am J Obstet Gynecol 2006; 195: 843– 847. 20 American College of Obstetricians and Gynecologists. Practice Bulletin No. 175: ultrasound in pregnancy. Obstet Gynecol 2016; 128: e241– e256. 21 American College of Obstetricians and Gynecologists. Practice Bulletin No. 151: cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. Obstet Gynecol 2015; 125: 1510– 1525. 22Pretlove SJ, Fox CE, Khan KS, Kilby MD. Noninvasive methods of detecting fetal anemia: a systematic review and meta-analysis. BJOG 2009; 116: 1558– 1567. 23Mari G, Deter RL, Carpenter RL, Rahman F, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal rd-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342: 9– 14. 24 Society for Maternal-Fetal Medicine; Dashe JS, Pressman EK, Hibbard JU. SMFM consult series #46: evaluation and management of polyhydramnios. Am J Obstet Gynecol 2018; 219: B2– B8. 25Cahill AG, Beigi R, Heine RP, Silver RM, Wax JR. Placenta accreta spectrum. Am J Obstet Gynecol 2018; 219: B2– B16. 26 Society for Maternal-Fetal Medicine Coding Committee. White paper coding for placenta accreta spectrum. Society for Maternal-Fetal Medicine website. https://urldefense.proofpoint.com/v2/url?u=https-3A__www.smfm.org_coding_white-2Dpapers_131-2Dsmfm-2Dcoding-2Dcommittee-2Dwhite-2Dpaper-2Dcoding-2Dfor-2Dplacenta-2Daccreta-2Dspectrum&d=DwIFAg&c=ST5Jxgx_zZ9nYuPWkSm01Luus8kzn0TCuX9tmQgnWms&r=zGmUNpEBZ3lV3CzGwAvJ1Q&m=qMcCxePdAWUEMj8v-ytjrUPNJxCvMYP5auJUmtISo-8&s=e_tiNmAAONIMTCggAg8Kh7zCZ_Jf9pV6h_E7iqDMqFE&e. Accessed June 11, 2019. 27Wax JR, Bookman L, Cartin A, Pinette MG, Blackstone J. Mild fetal cerebral ventriculomegaly: diagnosis, clinical associations, and outcomes. Obstet Gynecol Surv 2003; 58: 407– 414. 28Kapur RP, Mahony BS, Finch L, Siebert JR. Normal and abnormal anatomy of the cerebellar vermis in midgestational human fetuses. Birth Defects Res A Clin Mol Teratol 2009; 85: 700– 709. 29Santo S, D'Antonio F, Homfray T, et al. Counseling in fetal medicine: agenesis of the corpus callosum. Ultrasound Obstet Gynecol 2012; 40: 513– 521. 30Joó JG, Beke A, Szigeti Z, et al. Craniospinal malformations in a twelve-year fetopathological study: the efficiency of ultrasonography in view of fetopathological investigations. Early Hum Dev 2008; 84: 115– 119. 31Pugash D, Hendson G, Dunham CP, Dewar K, Money DM, Prayer D. Sonographic assessment of normal and abnormal patterns of fetal cerebral lamination. Ultrasound Obstet Gynecol 2012; 40: 642– 651. 32Rauff S, Kien TE. Ultrasound diagnosis of fetal neck masses: a case series [published online January 15, 2013]. Case Rep Obstet Gynecol. doi:https://doi.org/10.1155/2013/243590. 33Liberty G, Boldes R, Shen O, Shaul C, Cohen SM, Yagel S. The fetal larynx and pharynx: structure and development on two- and three dimensional ultrasound. Ultrasound Obstet Gynecol 2013; 42: 140– 148. 34McGahan MC, Ramos GA, Landry C, et al. Multislice display of the fetal face using 3-dimensional ultrasonography. J Ultrasound Med 2008; 27: 1573– 1581. 35Lee W, McNie B, Chaiworapongsa T, et al. Three-dimensional ultrasonographic presentation of micrognathia. J Ultrasound Med 2002; 21: 775– 781. 36Wang LM, Leung KY, Tang M. Prenatal evaluation of facial clefts by three-dimensional extended imaging. Prenat Diagn 2007; 27: 722– 729. 37Bethune M. Literature review and suggested protocol for managing ultrasound soft markers for Down syndrome: thickened nuchal fold, echogenic bowel, shortened femur, shortened humerus, pyelectasis and absent or hypoplastic nasal bone. Australas Radiol 2007; 51: 218– 225. 38Agathokleous M, Chaveeva P, Poon LCY, Kosinski P, Nicolaides KH. Meta-analysis of second-trimester markers for trisomy 21. Ultrasound Obstet Gynecol 2013; 41: 247– 261. 39Benacerraf BR. The history of the second-trimester sonographic markers for detecting fetal Down syndrome, and their current role in obstetric practice. Prenat Diagn 2010; 30: 644– 652. 40Cusick W, Provenzano J, Sullivan CA, Gallousis FM, Rodis JF. Fetal nasal bone length in euploid and aneuploid fetuses between 11 and 20 weeks’ gestation: a prospective study. J Ultrasound Med 2004; 23: 1327– 1333. 41Pilu G, Segata M. A novel technique for visualization of the normal and cleft fetal secondary palate: angled insonation and three-dimensional ultrasound. Ultrasound Obstet Gynecol 2007; 29: 166– 169. 42Wong HS, Tait J, Pringle KC. Viewing of the soft and the hard palate on routine 3-D ultrasound sweep of the fetal face: a feasibility study. Fetal Diagn Ther 2008; 24: 146– 154. 43Hofstaetter C, Plath H, Hansmann M. Prenatal diagnosis of abnormalities of the fetal venous system. Ultrasound Obstet Gynecol 2000; 15: 231– 241. 44Yagel S, Arbel R, Anteby EY, Raveh D, Achiron R. The three vessels and trachea view (3VT) in fetal cardiac scanning. Ultrasound Obstet Gynecol 2002; 20: 340– 345. 45Bahlmann F, Merz E, Hallermann C, Stopfkuchen H, Krämer W, Hofmann M. Congenital diaphragmatic hernia: ultrasonic measurement of fetal lungs to predict pulmonary hypoplasia. Ultrasound Obstet Gynecol 1999; 14: 162– 168. 46Moeglin D, Talmant C, Duyme M, Lopez AC. Fetal lung volumetry using two- and three-dimensional ultrasound. Ultrasound Obstet Gynecol 2005; 25: 119– 127. 47Metkus AP, Filly RA, Stringer MD, Harrison MR, Adzick NS. Sonographic predictors of survival in fetal diaphragmatic hernia. J Pediatr Surg 1996; 31: 148– 151. 48Ruano R, Molho M, Roume J, Ville Y. Prenatal diagnosis of fetal skeletal dysplasias by combining two-dimensional and three-dimensional ultrasound and intrauterine three-dimensional helical computer tomography. Ultrasound Obstet Gynecol 2004; 24: 134– 140. 49Dugoff L, Coffin CT, Hobbins JC. Sonographic measurement of the fetal rib cage perimeter to thoracic circumference ratio: application to prenatal diagnosis of skeletal dysplasias. Ultrasound Obstet Gynecol 1997; 10: 269– 271. 50Goetzinger KR, Cahill AG, Macones GA, Odibo AO. Echogenic bowel on second-trimester ultrasonography: evaluating the risk of adverse pregnancy outcome. Obstet Gynecol 2011; 117: 1341– 1348. 51Mailath-Pokorny M, Klein K, Klebermass-Schrehof K, Hachemian N, Bettelheim D. Are fetuses with isolated echogenic bowel at higher risk for an adverse pregnancy outcome? Experiences from a tertiary referral center. Prenat Diagn 2012; 32: 1295– 1299. 52McNamara A, Levine D. Intraabdominal fetal echogenic masses: a practical guide to diagnosis and management. Radiographics 2005; 25: 633– 645. 53van Vuuren SH, Damen-Elias HA, Stigter RH, et al. Size and volume charts of fetal kidney, renal pelvis and adrenal gland. Ultrasound Obstet Gynecol 2012; 40: 659– 664. 54Shen O, Rabinowitz R, Yagel S, Gal M. Absent gallbladder on fetal ultrasound: prenatal findings and postnatal outcome. Ultrasound Obstet Gynecol 2011; 37: 673– 677. 55Duguépéroux I, Scotet V, Audrézet MP, et al. Nonvisualization of fetal gallbladder increases the risk of cystic fibrosis. Prenat Diagn 2012; 32: 21– 28. 56Smrcek JM, Baschat AA, Germer U, Gloeckner-Hofmann K, Gembruch U. Fetal hydrops and hepatosplenomegaly in the second half of pregnancy: a sign of myeloproliferative disorder in fetuses with trisomy 21. Ultrasound Obstet Gynecol 2001; 17: 403– 409. 57Sepulveda W, Stagiannis KD, Flack NJ, Fisk NM. Accuracy of prenatal diagnosis of renal agenesis with color flow imaging in severe second-trimester oligohydramnios. Am J Obstet Gynecol 1995; 173: 1788– 1792. 58Kuleva M, Khen-Dunlop N, Dumez Y, Ville Y, Salomon LJ. Is complex gastroschisis predictable by prenatal ultrasound? BJOG 2012; 119: 102– 109. 59Lennon CA, Gray DL. Sensitivity and specificity of ultrasound for the detection of neural tube and ventral wall defects in a high-risk population. Obstet Gynecol 1999; 94: 562– 566. 60Dashe JS, Twickler DM, Santos-Ramos R, McIntire DD, Ramus RM. Alpha-fetoprotein detection of neural tube defects and the impact of standard ultrasound. Am J Obstet Gynecol 2006; 195: 1623– 1628. 61Schramm T, Gloning KP, Minderer S, et al. Prenatal sonographic diagnosis of skeletal dysplasias. Ultrasound Obstet Gynecol 2009; 34: 160– 170. 62Dighe M, Fligner C, Cheng E, Warren B, Dubinsky T. Fetal skeletal dysplasia: an approach to diagnosis with illustrative cases. Radiographics 2008; 28: 1061– 1077. 63Parilla BV, Leeth EA, Kambich MP, Chilis P, MacGregor SN. Antenatal detection of skeletal dysplasias. J Ultrasound Med 2003; 22: 255– 258. 64Bowerman RA. Anomalies of the fetal skeleton: sonographic findings. AJR Am J Roentgenol 1995; 164: 973– 979. 65Bromley B, Benacerraf B. Abnormalities of the hands and feet in the fetus: sonographic findings. AJR Am J Roentgenol 1995; 165: 1239– 1243. 66Holder-Espinasse M, Devisme L, Thomas D, et al. Pre- and postnatal diagnosis of limb anomalies: a series of 107 cases. Am J Med Genet A 2004; 124A: 417– 422. 67Stoll C, Wiesel A, Queisser-Luft A, Froster U, Bianca S, Clementi M. Evaluation of the prenatal diagnosis of limb reduction deficiencies. EUROSCAN Study Group. Prenat Diagn 2000; 20: 811– 818. 68Canto MJ, Cano S, Palau J, Ojeda F. Prenatal diagnosis of clubfoot in low-risk population: associated anomalies and long-term outcome. Prenat Diagn 2008; 28: 343– 346. 69Lev-Toaff AS, Ozhan S, Pretorius D, Bega G, Kurtz AB, Kuhlman K. Three-dimensional multiplanar ultrasound for fetal gender assignment: value of the mid-sagittal plane. Ultrasound Obstet Gynecol 2000; 16: 345– 350. 70Sepulveda W, Alcalde JL, Schnapp C, Bravo M. Perinatal outcome after prenatal diagnosis of placental chorioangioma. Obstet Gynecol 2003; 102: 1028– 1033. 71Lopriore E, Sueters M, Middeldorp JM, Klumper F, Oepkes D, Vandenbussche FP. Twin pregnancies with two separate placental masses can still be monochorionic and have vascular anastomoses. Am J Obstet Gynecol 2006; 194: 804– 808. 72Hasegawa J, Farian A, Nakamura M, et al. Analysis of the ultrasonographic findings predictive of vasa previa. Prenat Diagn 2010; 30: 1121– 1125. 73Gagnon R, Morin L, Bly S, et al. Guidelines for management of vasa previa. J Obstet Gynaecol Can 2009; 31: 748– 760. 74Malinger G, Lev D, Lerman-Sagie T. The fetal cerebellum: pitfalls in diagnosis and management. Prenat Diagn 2009; 29: 372– 380. 75Goldstein I, Tamir A, Zimmer EZ, Itskovitz-Eldor J. Growth of the fetal orbit and lens in normal pregnancies. Ultrasound Obstet Gynecol 1998; 12: 175– 179. 76 American Institute of Ultrasound in Medicine. Medical Ultrasound Safety. 3rd ed. Laurel, MD: American Institute of Ultrasound in Medicine; 2014. Citing Literature Volume38, Issue12December 2019Pages 3093-3100 ReferencesRelatedInformation" @default.
• W4249210216 created "2022-05-12" @default.
• W4249210216 date "2019-11-17" @default.
• W4249210216 modified "2023-10-16" @default.
• W4249210216 title "AIUM Practice Parameter for the Performance of Detailed Second‐ and Third‐Trimester Diagnostic Obstetric Ultrasound Examinations" @default.
• W4249210216 cites W1529574273 @default.
• W4249210216 cites W1540062588 @default.
• W4249210216 cites W1545146549 @default.
• W4249210216 cites W1558753090 @default.
• W4249210216 cites W1599865413 @default.
• W4249210216 cites W1764132625 @default.
• W4249210216 cites W1825998542 @default.
• W4249210216 cites W1869931471 @default.
• W4249210216 cites W1904933594 @default.
• W4249210216 cites W1930718057 @default.
• W4249210216 cites W1936591849 @default.
• W4249210216 cites W1963739606 @default.
• W4249210216 cites W1964591473 @default.
• W4249210216 cites W1967695449 @default.
• W4249210216 cites W1968220358 @default.
• W4249210216 cites W1974530501 @default.
• W4249210216 cites W1977103053 @default.
• W4249210216 cites W1981009960 @default.
• W4249210216 cites W1981475516 @default.
• W4249210216 cites W1984610940 @default.
• W4249210216 cites W1984794576 @default.
• W4249210216 cites W1986867459 @default.
• W4249210216 cites W1987225716 @default.
• W4249210216 cites W1988045038 @default.
• W4249210216 cites W1988360253 @default.
• W4249210216 cites W1992503867 @default.
• W4249210216 cites W2002367623 @default.
• W4249210216 cites W2010795274 @default.
• W4249210216 cites W2016195836 @default.
• W4249210216 cites W2020754422 @default.
• W4249210216 cites W2022734588 @default.
• W4249210216 cites W2031259147 @default.
• W4249210216 cites W2038290309 @default.
• W4249210216 cites W2044601446 @default.
• W4249210216 cites W2046065760 @default.
• W4249210216 cites W2046605924 @default.
• W4249210216 cites W2049602000 @default.
• W4249210216 cites W2051211149 @default.
• W4249210216 cites W2054524136 @default.
• W4249210216 cites W2056413527 @default.
• W4249210216 cites W2058747862 @default.
• W4249210216 cites W2063852054 @default.
• W4249210216 cites W2083354054 @default.
• W4249210216 cites W2096240070 @default.
• W4249210216 cites W2096504339 @default.
• W4249210216 cites W2097272818 @default.
• W4249210216 cites W2097653492 @default.
• W4249210216 cites W2110569204 @default.
• W4249210216 cites W2125811535 @default.
• W4249210216 cites W2126503856 @default.
• W4249210216 cites W2128698066 @default.
• W4249210216 cites W2134059188 @default.
• W4249210216 cites W2134441601 @default.
• W4249210216 cites W2144898493 @default.
• W4249210216 cites W2147948220 @default.
• W4249210216 cites W2157644565 @default.
• W4249210216 cites W2161939468 @default.
• W4249210216 cites W2164063056 @default.
• W4249210216 cites W2169861594 @default.
• W4249210216 cites W2170801538 @default.
• W4249210216 cites W2237547002 @default.
• W4249210216 cites W2262118304 @default.
• W4249210216 cites W2327298317 @default.
• W4249210216 cites W2439111937 @default.
• W4249210216 cites W2883743916 @default.
• W4249210216 cites W2901857044 @default.
• W4249210216 cites W4211075899 @default.
• W4249210216 cites W4211123156 @default.
• W4249210216 cites W4211194784 @default.
• W4249210216 cites W4231925531 @default.
• W4249210216 cites W4240064556 @default.
• W4249210216 cites W4246275754 @default.
• W4249210216 cites W4251245750 @default.
• W4249210216 cites W4255943575 @default.
• W4249210216 doi "https://doi.org/10.1002/jum.15163" @default.
• W4249210216 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31736130" @default.
• W4249210216 hasPublicationYear "2019" @default.
• W4249210216 type Work @default.
• W4249210216 citedByCount "42" @default.
• W4249210216 countsByYear W42492102162020 @default.
• W4249210216 countsByYear W42492102162021 @default.
• W4249210216 countsByYear W42492102162022 @default.
• W4249210216 countsByYear W42492102162023 @default.
• W4249210216 crossrefType "journal-article" @default.
• W4249210216 hasBestOaLocation W42492102161 @default.
• W4249210216 hasConcept C126838900 @default.
• W4249210216 hasConcept C131872663 @default.
• W4249210216 hasConcept C143753070 @default.
• W4249210216 hasConcept C172680121 @default.
• W4249210216 hasConcept C19527891 @default.
• W4249210216 hasConcept C2779234561 @default.
• W4249210216 hasConcept C2993596548 @default.
• W4249210216 hasConcept C3018313082 @default.

• next